Total Payments
$137,534
2024 Payments
$5,471
Companies
16
Transactions
123
Payment Breakdown by Category
Consulting$106,567 (77.5%)
Other$12,470 (9.1%)
Travel$10,241 (7.4%)
Research$5,831 (4.2%)
Food & Beverage$2,425 (1.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $106,567 | 45 | 77.5% |
| Travel and Lodging | $10,241 | 27 | 7.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,970 | 3 | 5.8% |
| Unspecified | $5,831 | 9 | 4.2% |
| Honoraria | $4,500 | 1 | 3.3% |
| Food and Beverage | $2,425 | 38 | 1.8% |
Payments by Type
General
$131,703
114 transactions
Research
$5,831
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ACADIA Pharmaceuticals Inc | $61,221 | 46 | $0 (2021) |
| Avanir Pharmaceuticals, Inc. | $22,484 | 19 | $0 (2021) |
| Genentech, Inc. | $17,268 | 11 | $0 (2023) |
| Genentech USA, Inc. | $8,495 | 6 | $0 (2021) |
| H. Lundbeck A S | $5,710 | 5 | $0 (2022) |
| Corium, LLC | $4,950 | 2 | $0 (2022) |
| Eli Lilly and Company | $4,658 | 5 | $0 (2022) |
| Biogen, Inc. | $3,171 | 3 | $0 (2021) |
| Lundbeck LLC | $3,000 | 1 | $0 (2024) |
| Novo Nordisk Inc | $2,430 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,471 | 3 | Lundbeck LLC ($3,000) |
| 2023 | $5,170 | 2 | Genentech, Inc. ($5,170) |
| 2022 | $19,294 | 16 | Genentech, Inc. ($7,985) |
| 2021 | $18,780 | 11 | ACADIA Pharmaceuticals Inc ($6,975) |
| 2020 | $47,262 | 29 | ACADIA Pharmaceuticals Inc ($37,325) |
| 2019 | $21,246 | 23 | ACADIA Pharmaceuticals Inc ($7,150) |
| 2018 | $12,194 | 18 | ACADIA Pharmaceuticals Inc ($9,771) |
| 2017 | $8,116 | 21 | Avanir Pharmaceuticals, Inc. ($4,505) |
All Payment Transactions
123 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/28/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $40.51 | General |
| Category: Psychology/Psychiatric | ||||||
| 04/10/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $2,430.00 | General |
| 01/29/2024 | Lundbeck LLC | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: PSYCHIATRY | ||||||
| 08/14/2023 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,350.00 | General |
| 02/24/2023 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,820.00 | General |
| 12/13/2022 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $830.00 | General |
| 12/07/2022 | Corium, LLC | Adlarity (Drug) | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| Category: Treatment of dementia of the Alzheimers type | ||||||
| 10/19/2022 | Corium, LLC | ADLARITY (Drug) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: Treatment of dementia of the Alzheimers type | ||||||
| 10/06/2022 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,245.00 | General |
| 09/09/2022 | Sumitomo Pharma Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $6.90 | General |
| 09/07/2022 | H. Lundbeck A S | REXULTI (Drug) | Honoraria | Cash or cash equivalent | $4,500.00 | General |
| Category: PSYCHIATRY | ||||||
| 09/07/2022 | H. Lundbeck A S | REXULTI (Drug) | Travel and Lodging | In-kind items and services | $402.20 | General |
| Category: PSYCHIATRY | ||||||
| 09/07/2022 | H. Lundbeck A S | REXULTI (Drug) | Travel and Lodging | In-kind items and services | $331.80 | General |
| Category: PSYCHIATRY | ||||||
| 09/07/2022 | H. Lundbeck A S | REXULTI (Drug) | Travel and Lodging | In-kind items and services | $312.00 | General |
| Category: PSYCHIATRY | ||||||
| 09/07/2022 | H. Lundbeck A S | REXULTI (Drug) | Food and Beverage | In-kind items and services | $164.00 | General |
| Category: PSYCHIATRY | ||||||
| 08/01/2022 | EISAI INC. | — | Food and Beverage | Cash or cash equivalent | $102.53 | General |
| 07/27/2022 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,245.00 | General |
| 06/10/2022 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,660.00 | General |
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $540.00 | Research |
| Study: ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY | ||||||
| 04/19/2022 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,245.00 | General |
| 03/31/2022 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,760.00 | General |
| 12/14/2021 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,555.00 | General |
| 12/03/2021 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $622.50 | General |
| 08/26/2021 | Eli Lilly and Company | — | — | In-kind items and services | $307.95 | Research |
| Study: ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY | ||||||
| 06/17/2021 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,935.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $2,005 | 1 |
| A 24-MONTH, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, SAFETY, TOLERABILITY, BIOMARKER, AND PHARMACOKINETIC STUDY OF AZD3293 IN EARLY ALZHEIMERS DISEASE -THE AMARANTH STUDY | Eli Lilly and Company | $1,535 | 1 |
| Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD | Takeda Pharmaceuticals U.S.A., Inc. | $1,174 | 4 |
| ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY | Eli Lilly and Company | $1,118 | 3 |
About Dr. Jacobo Mintzer, MD
Dr. Jacobo Mintzer, MD is a Psychiatry healthcare provider based in Charleston, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1518075563.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jacobo Mintzer, MD has received a total of $137,534 in payments from pharmaceutical and medical device companies, with $5,471 received in 2024. These payments were reported across 123 transactions from 16 companies. The most common payment nature is "Consulting Fee" ($106,567).
Ad
Practice Information
- Specialty Psychiatry
- Location Charleston, SC
- Active Since 08/29/2006
- Last Updated 08/24/2011
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1518075563
Products in Payments
- NUPLAZID (Drug) $51,096
- REXULTI (Drug) $8,710
- Non-Covered Product (Drug) $6,910
- NUEDEXTA (Drug) $4,366
- DISEASE EDUCATION (Drug) $3,600
- Adlarity (Drug) $3,150
- ADLARITY (Drug) $1,800
- Actos (Drug) $1,174
- Albutein (Biological) $747.98
- ONZETRA Xsail (Drug) $117.08
- Auvelity (Drug) $40.51
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Charleston
Dr. Melissa Moody, M.d, M.D
Psychiatry — Payments: $1.0M
Psychiatry $1.0M
Ricardo Fermo, Md, MD
Psychiatry — Payments: $253,995
Psychiatry $253,995
James Ballenger, M.d, M.D
Psychiatry — Payments: $65,468
Psychiatry $65,468
Dr. Fahd Mousa, M.d, M.D
Psychiatry — Payments: $49,339
Psychiatry $49,339
Kathleen Brady, Md, MD
Psychiatry — Payments: $48,881
Psychiatry $48,881
Scott Christie, M.d, M.D
Psychiatry — Payments: $29,585
Psychiatry $29,585